Abstract
Reactive arthritis (ReA) was known as Reiter's disease or Fiessinger-Leroy disease for nearly 100 years. However, during the past 30 years the disease has been known as reactive arthritis, a member of the spondyloarthritis family. Despite knowing the initiating event (infection) and genetic constitution (many patients have HLA-B27) of ReA, a model of interplay between environment and genetics, its pathogenesis is still incompletely known. This review covers the epidemiology, clinical features, treatment, and prognosis of ReA.
MeSH terms
-
Adult
-
Age Distribution
-
Anti-Bacterial Agents / therapeutic use
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Arthritis, Reactive / drug therapy
-
Arthritis, Reactive / epidemiology*
-
Arthritis, Reactive / immunology
-
Arthritis, Reactive / microbiology*
-
Drug Therapy, Combination
-
Female
-
Finland / epidemiology
-
HLA-B27 Antigen / immunology*
-
Humans
-
Incidence
-
Male
-
Middle Aged
-
Prognosis
-
Prohibitins
-
Risk Assessment
-
Severity of Illness Index
-
Sex Distribution
Substances
-
Anti-Bacterial Agents
-
Anti-Inflammatory Agents, Non-Steroidal
-
HLA-B27 Antigen
-
PHB2 protein, human
-
Prohibitins